
London —
UK
ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines in Europe that is committed to improving the lives of patients by enhancing the critical medicines they depend on.
With the agility of a virtual business but the reassurance that comes with a heritage spanning decades, smart thinking, innovation and a passion for enhancing medicines to broaden access and improve patient health outcomes is at the heart of our business. This is reflected in the work we do, how we do it and the people who deliver it.
As the go to partner for commercialising complex medicines in European hospitals, our agile and highly experienced teams in marketing, direct sales, market access and medical work across major European markets to broaden access, choice and availability while our established products business with its portfolio of more than 180 molecules provides essential medicines globally to the patients that need them.
Download the ADVANZ PHARMA® Corporate Brochure
ADVANZ PHARMA has an operational headquarters in London, an operations centre of excellence in Mumbai, offices in Geneva and Paris and commercial affiliates in North America, Europe and Australia/NZ, together with an established global network of commercial partners throughout the rest of the world
UK
Ireland
Australia
India
Sweden
USA
Switzerland
France
UK
Home to our Global Head Office, London is where our Executive Leadership Team is based along with our corporate and operational functions. In total, we have over 100 employees here.
Ireland
We have over 10 employees in Dublin who make up our Global Supplier Alliance Management and Ireland Commercial teams.
Australia
Our Australasian office is based in Sydney, Australia. It’s where we serve Australia, New Zealand and the Pacific Island countries from. Our 25 employees here work across Business Development, Finance, Regulatory Affairs, Supply Chain and Sales.
India
Shared Service Centre and India Management Team
Sweden
Business Development, Finance, Quality, Regulatory Affairs, Supply Chain and Sales
USA
Clinical Affairs, Commercial, Regulatory, Quality and Finance, legal and supply chain
Switzerland
France
The success of any company is driven by its people. We are no different. Our teams are made up of people who come from all walks of life and backgrounds, and thrive in an environment where diversity is celebrated but where we are all united by the same passion, to help improve the lives of patients by enhancing the critical medicines they depend on.
Our lean and virtual model combined with our responsive and highly experienced teams mean that we are ready to be flexible and adapt to changing situations at a moment’s notice. As a company, we are proud to say we are small enough to care but big enough to make a difference.
ADVANZ PHARMA is committed to investing in the growth of our people and rewarding and recognising the contribution they make while providing a unique culture that includes a collaborative and flexible working environment – our people are encouraged to work up to 3 days a week remotely, helping them operate at the very best of their ability while ensuring work life balance.
Help people lead better lives with medicines, that without our focus, may not be available.
Our values reflect who we are and what we stand for. Having a purpose, goal and values would mean nothing, however, if we didn’t have the people to bring them to life, to share the journey and vision of building a company we believe in. From London to Mumbai, Helsingborg to Sydney and Geneva to Chicago, resilience and common values have united ADVANZ PHARMA, regardless of geography or remote working situation.
We work together, combining the intellectual power of our global, multicultural workforce to find ways to improve the lives of patients.
We don’t sit back. We constantly strive to create new opportunities that deliver value.
We empower our people to use good judgement to make the right choices, enabling them to grow within the company.
We believe in open and transparent relationships, both internally and externally. We aim to be accessible to our partners, customers and patients; we strive to deliver the best possible service.
We insist on the highest ethical behaviour in all aspects of our work. We operate in a highly complex and competitive environment, but we always aim to do what’s right for the healthcare systems and patients we serve.
At ADVANZ PHARMA, our European hospital portfolio of complex medicines focuses on Anti-infectives, Endocrinology and Critical Care medicines. This is bolstered by an established brands business unit of more than 180 molecules sold into 100 countries across a wide range of therapy areas such as CVD, pain management, ophthalmology, urology, and central nervous system disorders.
Over the years, we have successfully expanded our portfolio through targeted licensing and acquisitions and are well positioned for growth. We continue to work closely with our partners to enhance our medicines and add value through innovation, particularly in the anti-infectives space which has had limited investment in recent years, despite the ever-increasing health burden of antimicrobial resistance.
But this is not always easy – either because the divestor company has discontinued the manufacture of a medicine and an alternative manufacturer needs to be found or a medicine was originally developed several decades ago which means it can be difficult to manufacture without significant investment to bring it up to date in line with current regulatory requirements.
Our experience of supplying and developing niche established medicines for decades means we have a rich heritage of acquiring and investing in these valuable medicines through targeted development, product in-licensing and acquisition to bring them to more markets or by improving product formulation and strength to optimise treatment so that patients can continue to use them for years to come.
Over the last 15 years, we have acquired more than 15 legacy brands for our international markets and approx. 10 brands for the US market meaning more patients are able to continue to access them.
Over the last 10 years, we have worked across 20 initiatives to optimise or revitalize medicines to enhance patient care and provide greater choice.
We have a proud heritage and successful track record of business and product acquisitions and company assets around the world, including BNM in Australia, Focus Pharmaceuticals in the UK, and Abcur in the Nordics and Correvio in Europe.
At ADVANZ PHARMA, we have been supplying and developing niche established medicines for decades and have a rich heritage of acquiring and investing in these medicines so that patients who need them can continue to get them.
ADVANZ PHARMA is committed to conducting its business ethically and in compliance with all applicable laws, regulations, guidelines, and policies. ADVANZ PHARMA has established and implemented a Code of Conduct (the “Code”), which sets forth ADVANZ PHARMA's commitment to ethical business conduct.
The Compliance Officer is responsible for overseeing the administration and implementation of ADVANZ PHARMA’s compliance program and will report at least quarterly to the Compliance Committee. The Compliance Officer has authority to direct and implement compliance-related changes and to determine the corporate response to compliance-related matters.
ADVANZ PHARMA has established a Compliance Committee and the committee meets on a quarterly basis. The Compliance Committee is responsible for ensuring the implementation and effectiveness of the Compliance Program, and to provide advice and support to the Compliance Officer.
ADVANZ PHARMA policies and procedures were developed to ensure that interactions with healthcare professionals are appropriate, ethical, and consistent with applicable laws and standards. ADVANZ PHARMA expects its employees to comply with the compliance program, its Code of Conduct, policies, procedures, and all applicable laws. Employees must annually acknowledge their responsibility and commitment to conduct ADVANZ PHARMA’s business consistent with these standards and to report to real or suspect violations. Employees who violate these standards are subject to appropriate disciplinary action, up to and including termination. ADVANZ PHARMA’s policies prohibit retaliation against any employee for making a good faith report.
ADVANZ PHARMA is committed to an environment in which open communications are encouraged, including questions or concerns about the compliance program. Employees are required to report any activity or individual that is suspect or in violation of the compliance program. Employees may contact direct managers, the Chief Executive Officer, the Chief Financial Officer, the Compliance Officer or the Compliance Committee at compliance@advanzpharma.com or they may use the Compliance Hotline by calling 855-562-5982. The Hotline is available 24 hours a day/7 days a week to allow confidential and anonymous reporting.
The compliance program includes activities designed to monitor and audit compliance with ADVANZ PHARMA policies and procedures. The Compliance Officer oversees monitoring and auditing through an audit plan, including internal and external auditing activities. The Compliance Officer works with relevant resources to evaluate audit findings and ensure the implementation of any corrective action. The Compliance Officer (or designee) reviews and evaluates concerns to determine the required investigative response.
If it is determined that noncompliant conduct has occurred, appropriate parties are responsible for corrective and/or disciplinary actions. ADVANZ PHARMA’s disciplinary actions may include the following: termination; disciplining any involved employee(s); disciplining supervisor for failure to monitor employees appropriately. ADVANZ PHARMA’s corrective and preventative actions may include: revising the compliance program, policies, and/or procedures; revising the role of the Compliance Committee; increased auditing and monitoring; revising the training program.
As ADVANZ PHARMA evolves as a company and as regulations change, it may amend its compliance program. The Compliance Committee reviews and approves all suggested changes. The Compliance Officer shall be responsible for communicating changes in the compliance program to employees.
As part of ADVANZ PHARMA’s continuing commitment to corporate compliance, ADVZ declares that, to the best of its knowledge, and based on a good faith understanding of the statutory requirements of California Health and Safety Code § 119400 and 119402, it has adopted a Comprehensive Compliance Program as mandated by this California law. To the best of our knowledge, as of November 1, 2017, ADVZ believes that it is in compliance with its Comprehensive Compliance Program and its good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402.
Additionally, to comply with California law, ADVZ has established a maximum annual aggregate dollar limit of $1,500 for gifts, promotional materials or activities provided to California health care professionals. This dollar limit represents a spending cap, not a goal or average, and typically the amount spent per physician is anticipated to be substantially less than this maximum amount.
For questions about our Comprehensive Compliance Program or to obtain a copy, please contact us at compliance@advanzpharma.com.
Steffen joined ADVANZ PHARMA as CEO in April 2022 and has broad general management experience in international life science businesses. He is a medical doctor by training, has previously held senior roles with STADA, Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain. His industry experience covers Biotech, Pharma, MedTech, Biosimilars, Generics, and OTC. He lead businesses in context of large European-based multinational Pharmaco, US-based Biotech, and Private Equity portfolio companies and likes to work with strong teams to drive business growth, transformation, and M&A
Andreas Stickler joined ADVANZ PHARMA from Merck Healthcare, part of Merck KGaA, where he was Chief Financial Officer and also served as Global Head of M&A and Business Development for many years. Before that, he held several finance roles at Hoechst/Aventis and Degussa/Evonik in Treasury, Capital Markets and Risk Management and brings a wealth of Finance, Healthcare and M&A expertise to the team.
Karl has more than 30 years of experience in manufacturing, packaging, supply chain and distribution, and 20 years in senior management and leadership positions including his role as Operations Director for Teva. As Chief Operations Officer for ADVANZ PHARMA, Karl leads all operations functions globally, including scientific affairs (medical, regulatory and quality), supply (supply chain and supplier alliance management), new product introductions and technical operations.
Paul joined ADVANZ PHARMA from Teva in September 2016 in the role of Vice President UK&I Commercial. His diverse commercial career spans 20 years and also includes marketing and commercial strategy roles at Smiths Medical Systems, IVAX Pharmaceuticals, Merck Generics (Mylan) and Arrow Generics (Watson Pharmaceuticals). In 2009 Paul moved into consultancy working as a Director at Fleishman-Hillard (an Omnicom communications consultancy), where he managed international communications programmes for Bristol Myers Squibb and Philips. In 2013, he joined Teva, where he had board level responsibility for the largest generics business in the UK. As Chief Commercial Officer of the Strategic Growth Unit, Paul leads the commercial operations in the UK & Ireland, our in-market sales & marketing capabilities across Europe and the Corporate Communications function.
Susanna brings over 15 years of leadership experience in the pharmaceutical industry, specialising in leading buy and build initiatives, transformational turnarounds, organic pipeline development, and devising and implementing strategic plans for geographic expansion. Susanna is responsible for M&A, BD&L and Data and Market Intelligence at ADVANZ and will drive the development and execution of the company’s growth plans.
Prior to joining ADVANZ, she played a pivotal role in the establishment and growth of PE-backed Theramex, where she was part of the core management team who carved-out more than 20 assets across multiple geographies to create a stand-alone specialty pharmaceutical company.
Fiona Huzarski has worked for over 20 years as a senior HR professional, 15 years within the Pharmaceuticals industry. As Vice President of Global HR, she is responsible for leading the Global HR function and setting the People Strategy to create an inclusive, flexible and collaborative environment where all employees can grow and develop in support of the company’s long-term goals.
Prior to joining ADVANZ PHARMA as Vice President of Global HR in August 2019, she was Global HR Director at Britannia Pharmaceuticals, part of the STADA group. Her career started in the Management Consulting sector before joining GSK’s Global Recruitment Team and working for 10 years at UCB in various Senior HR roles, supporting the Commercial, R&D and Technical Operations functions in both UK & Ireland and across Europe. She is a Fellow of the Chartered Institute of Personnel & Development (CIPD) and holds a Post graduate Diploma in Human Resource Management from Thames Valley University.
Anke joined ADVANZ PHARMA in October 2021. She brings over 15 years’ experience from strategic and operational management positions in the pharmaceutical and consulting industry and will be essential in leading the company’s transformation journey as it continues its expansion focusing on commercialising complex medicines in Europe to even better serve our patients and customers.
A pharmacist by training, she holds a PhD in molecular biology. Prior to joining ADVANZ PHARMA, Anke worked at McKinsey, HgCapital and most recently, held various global roles across Strategy, Launch and Portfolio Management as well building and driving the local German ehealth Strategy at Sandoz.
Before she was appointed as Group General Counsel for ADVANZ PHARMA in May 2022, Eve-Anadel Coronado joined Concordia International in 2018 and supported the M&A and BD&L teams. Eve has broad legal experience in international life sciences and held roles at Hikma Pharmaceuticals, Pharmascience and IQVIA (formerly IMS Health) where she worked in the R&D, Scientific Affairs, Business Development, M&A, Global Operations, Supply Chain, Commercial, Marketing and Sales teams. Before venturing into life sciences, Eve also worked for law firms in Paris and Montreal. Eve speaks French, Spanish and English fluently.
Simon started his pharmaceutical career as a Medical Representative with Pfizer Ltd in the UK. In 2000 he joined Goldshield and held various International Regional Management positions in the Middle East, Asia and Europe. He then joined the International division of Stiefel Laboratories with particular focus on the Middle East and Africa. Simon joined Amdipharm in 2006 and was instrumental in establishing its Latin American business. In 2011, he became the Director of Alliance Management and in 2013 he was appointed International Commercial Director. As President, International & North America Simon leads our commercial operations in these regions.
Dr Nick Warwick has over 30 years of experience both in the pharmaceutical industry and as a medical doctor. Nick trained as a medical Doctor at Charing Cross Hospital Medical School in London, now part of the Imperial College group, and spent 10 years in clinical medicine rotating through disciplines including emergency medicine, rheumatology and rehabilitation, dermatology, ear nose and throat surgery, obstetrics and gynaecology, and primary care, before joining the Pharmaceutical Industry in 1997 as Medical Adviser for Abbott. In the following 24 years, Nick held senior country level, regional and global leadership roles within Medical Affairs and Clinical Development (Abbott and Abbvie) and was Chief Medical Officer for Sandoz (2014-2019). Nick joined ADVANZ PHARMA as Chief Medical Officer in June 2020. He is responsible for setting the medical vision and strategic direction for the Medical Office (comprising medical affairs, patient safety, clinical development and medical compliance functions), ensuring that ADVANZ PHARMA has the right resources, skills and capabilities to meet its growing business needs and that the voice of the patient and healthcare professional is fully represented in all company decisions.
Nick holds a Bachelor of Medicine, Bachelor of Surgery from Charing Cross Hospital Medical School, London (MBBS, 1986), and a Diploma from the Royal College of Obstetrics and Gynaecologists, London (DRCOG, 1992) and a Diploma of Pharmaceutical Medicine from the University of Wales, Cardiff (DPM, 1998). He has been a Fellow of the Faculty of Pharmaceutical Physicians (FFPM) since 2010.
Chris joined ADVANZ PHARMA in January 2022 and brings over 25 years of pharmaceutical industry experience in R&D, project management and business/corporate development. He previously led Global M&A activities at both Neuraxpharm and Sandoz in addition to holding senior corporate development roles at Sanofi and GSK and has executed transactions across multiple jurisdictions and therapeutic areas. Having originally trained as a scientist, Chris has also spent time in financial advisory exclusively focused on the biopharma sector.
Steffen joined ADVANZ PHARMA as CEO in April 2022 and has broad general management experience in international life science businesses. He is a medical doctor by training, has previously held senior roles with STADA, Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain. His industry experience covers Biotech, Pharma, MedTech, Biosimilars, Generics, and OTC. He led businesses such as large European-based multinational Pharmaco, US-based Biotech, and Private Equity portfolio companies and likes to work with strong teams to drive business growth, transformation, and M&A.
Andreas Stickler joined ADVANZ PHARMA from Merck Healthcare, part of Merck KGaA, where he was Chief Financial Officer and also served as Global Head of M&A and Business Development for many years. Before that, he held several finance roles at Hoechst/Aventis and Degussa/Evonik in Treasury, Capital Markets and Risk Management and brings a wealth of Finance, Healthcare and M&A expertise to the team.
Joined in May 2015. Raj has over 25 years of experience in the healthcare industry. He is Head of the Healthcare sector team and he is the responsible advisor for Nordic Capital investments in the sector. Raj holds several non-executive positions including the boards of ERT, ArisGlobal, Alloheim and Royal Brompton and Harefield Hospitals Charity. Prior to joining, Raj’s healthcare experience spans both working as a practitioner, having initially qualified and practiced as a cardiac surgeon at Oxford, through to extensive transactional experience gained as Co-Head of Goldman Sachs healthcare investment banking practice where he advised private equity and corporate clients. Raj holds degrees in medicine and surgery from Imperial College, London as well as being Fellow of the Royal College of Surgeons and an MBA from London Business School.
Rainer joined in June 2019, as a Partner and Co-Head of the DACH region with focus on Nordic Capital’s core sectors Healthcare, Technology & Payments and Financial Services. Rainer joined from Goldman Sachs where he was Managing Director focusing on European healthcare companies. He is of German origin and started his career at McKinsey & Company, working across various industries in the DACH region. Rainer studied business administration at WHU Koblenz and holds a doctorate/PhD from Friedrich-Alexander-Universität Erlangen-Nürnberg.
he following entities are all trading divisions of ADVANZ PHARMA Corp.
Mercury Pharmaceuticals Ltd
Amdipharm Ltd
Focus Pharmaceuticals Ltd
Advanz Pharma Generics (UK) Ltd
Advanz Pharma Services (UK) Ltd
Abcur AB
BNM (Boucher & Muir PTY Limited – Australia)
Pinnacle
Direct: +44 (0) 208 588 9100
Fax: +44 (0) 208 588 9200
Direct: +353 (0)1 6971640
Fax: +353 (0)1 6971642
Commercial / Customer Support +353 1 5294230
+49 (0) 800 1840 212 (Attention: new phone number)
Medical Information: medicalinformation@advanzpharma.com
Direct: +4642 135 770
Fax: +4642 135 771
General queries: enquiries@advanzpharma.com
Product queries: medicalinformation@advanzpharma.com
Direct: +612 9431 6333
Phone: +1 877 370 1142
PINNACLE BIOLOGIS
Global Headquarters
2801 Lakeside Drive
Suite 210
Bannockburn, IL 60015
Direct: +1 847 283 7690
Direct. +44 (0) 208 588 9100
Fax. +44 (0) 208 588 9200
Direct: +91 22 6678 4444
Fax: +91 22 6677 1262
Direct: +44 (0) 208 588 9100
enquiries@advanzpharma.com
tel: +41 (0) 84 800 79 70
fax: +41 (0) 22 907 79 71
Tel. : +33 (0)1 77 68 89 17
Fax: +33 (0)1 85 78 76 43
www.advanzpharma.com
enquiries@advanzpharma.com
he following entities are all trading divisions of ADVANZ PHARMA Corp.
Mercury Pharmaceuticals Ltd
Amdipharm Ltd
Focus Pharmaceuticals Ltd
Advanz Pharma Generics (UK) Ltd
Advanz Pharma Services (UK) Ltd
Abcur AB
BNM (Boucher & Muir PTY Limited – Australia)
Pinnacle
Direct: +44 (0) 208 588 9100
Fax: +44 (0) 208 588 9200
Direct: +353 (0)1 6971640
Fax: +353 (0)1 6971642
Commercial / Customer Support +353 1 5294230
+49 (0) 800 1840 212 (Attention: new phone number)
Medical Information: medicalinformation@advanzpharma.com
Direct: +4642 135 770
Fax: +4642 135 771
General queries: enquiries@advanzpharma.com
Product queries: medicalinformation@advanzpharma.com
Direct: +612 9431 6333
Phone: +1 877 370 1142
PINNACLE BIOLOGIS
Global Headquarters
2801 Lakeside Drive
Suite 210
Bannockburn, IL 60015
Direct: +1 847 283 7690
Direct. +44 (0) 208 588 9100
Fax. +44 (0) 208 588 9200
Direct: +91 22 6678 4444
Fax: +91 22 6677 1262
Direct: +44 (0) 208 588 9100
enquiries@advanzpharma.com
tel: +41 (0) 84 800 79 70
fax: +41 (0) 22 907 79 71
Tel. : +33 (0)1 77 68 89 17
Fax: +33 (0)1 85 78 76 43
www.advanzpharma.com
enquiries@advanzpharma.com
INFORMATION REGARDING FORMAL SALE PROCESS
ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION IN THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH ANY CONSENT OR OTHER FORMALITY WHICH ADVANZ PHARMA CORP. LIMITED REGARDS AS UNDULY ONEROUS.
You are attempting to enter the area of this website that is designated for the publication of documents and information in connection with ADVANZ PHARMA Corp. Limited (“ADVANZ”) formal sale process.
The information contained in this area of this website is being made available in good faith and for information purposes only in compliance with the City Code on Takeovers and Mergers and is subject to the terms and conditions set out below. In particular, the information contained in this area of this website does not constitute an offer to sell or otherwise dispose of or any invitation or solicitation of any offer to purchase or subscribe for any securities in any jurisdiction in which such offer or solicitation is unlawful.
Access to the Website
If you would like to view this area of the website, please read this notice carefully. This notice applies to all persons who view this area of the website and, depending on where you are located, may affect your rights or responsibilities. ADVANZ reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit this area of the website. In addition, the contents of this area of the website may be amended at any time in whole or in part at the sole discretion of ADVANZ.
Overseas Persons
As a consequence of legal restrictions, the release, publication or distribution of information contained in this area of the website in certain jurisdictions or to certain persons may be restricted or unlawful. All persons resident or located outside the United Kingdom who wish to view this area of the website must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so and should inform themselves of, and observe, any applicable legal or regulatory requirements applicable in their jurisdiction. If you are resident or located in a country that renders the accessing of this area of the website or parts thereof illegal, whether or not subject to making certain notifications or taking other action, you should not view this area of the website.
It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should not continue to seek to access this area of the website.
You should not forward, transmit or show the announcements, information or documents contained in this area of the website to any person. In particular, you should not forward or transmit the announcements, information or documents contained in this area of the website to any jurisdiction where it would be unlawful to do so.
Forward Looking Statements
This area of the website contains “forward-looking statements”. These statements are based on the current expectations of the management of ADVANZ and are naturally subject to uncertainty and changes in circumstances.
Forward-looking statements include, without limitation, statements typically containing words such as “intend”, “expect”, “anticipate”, “target”, “estimate”, “plan”, “strategy”, “will”, “should”, “may”, “goal”, “seek”, “believe”, “predict”, “continue”, “future”, “could”, “can” and words of similar import. These forward looking statements are not guarantees of future performance. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements. These factors include, but are not limited to, changes in economic conditions, changes in the level of capital investment, success of business and operating initiatives and restructuring objectives, costs associated with research and development, changes in the prospects for products in the research and development pipeline of ADVANZ, customers’ strategies and stability, changes in the regulatory environment, fluctuations of interest and exchange rates, the outcome of litigation, government actions and natural phenomena such as floods, earthquakes and hurricanes. Other unknown or unpredictable factors could cause actual results to differ materially from those in the forward-looking statements. ADVANZ does not undertake any obligation to update publicly or revise forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required.
Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Neither ADVANZ nor any of its affiliated companies undertakes any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required.
Responsibility
In relation to any document, announcement or information contained in this area of the website, the only responsibility accepted by the directors of ADVANZ (the “Responsible Persons”) is for the correctness and fairness of its reproduction or presentation, unless the responsibility statement in any relevant document expressly provides otherwise.
None of the Responsible Persons, ADVANZ or its affiliated companies have reviewed and none of them is responsible for, or accepts any liability in respect of, any information on any other website that may be linked to this website by a third party.
The documents included in this area of the website speak only at the specified date of the relevant document and neither ADVANZ nor any of its affiliated companies has or accepts any responsibility or duty to update such documents (other than to the extent such duty arises as a matter of law).
If you are in any doubt about the contents of this area of the website or the action you should take, you should seek your own financial advice from an independent financial adviser authorised under the Financial Services and Markets Act 2000 or, if you are located outside the United Kingdom, from an appropriately authorised independent financial adviser.
THE DOCUMENTS IN THIS AREA OF THE WEBSITE MAY NOT BE DOWNLOADED, FORWARDED, TRANSMITTED OR SHARED WITH ANY OTHER PERSON EITHER IN WHOLE OR IN PART WHERE TO DO SO WOULD OR MAY CONSTITUTE A BREACH OF ANY APPLICABLE LOCAL LAWS OR REGULATIONS.
Electronic versions of these materials are not directed at or accessible by persons resident in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.
This notice shall be governed by, and interpreted in accordance with, English law.
Confirmation of Understanding and Acceptance of Disclaimer. If you do not click “I AGREE” below you will not be permitted access to this area of the website.